ISSN 1354-3784
2 papers in the library · 10 citations · publishing 2022-2023
Expert Opinion on Investigational Drugs October 3, 2023 Zofia Kozak, Matthew W Johnson, Scott T Aaronson 10 citations
Patients with treatment-resistant depression may be the most suitable candidates for psilocybin treatment when weighing known risks and benefits against existing standards of care. Much remains unknown about the risks of psilocybin treatment.
Expert Opinion on Investigational Drugs February 1, 2022 L. Averill, C. Abdallah
Only two FDA-approved medications exist for PTSD, both SSRIs, which have limited efficacy: 40% of patients do not respond, only 20-30% achieve remission, and the advantage over placebo is 10-20%. Psychotherapy also has high dropout rates, with 55.8% for Prolonged Exposure and 46.6% for Cognitive Processing Therapy. There is an urgent need for novel treatments. Psychoplastogens such as ketamine, MDMA, psilocybin, and 5-MeO-DMT, which rapidly promote neural plasticity, show potential for fast and robust improvements in trauma-related symptoms. Ketamine's rapid-acting antidepressant effects have prompted a paradigm shift toward targeting synaptic dysconnectivity underlying chronic stress pathology, rather than focusing on single neurotransmitter systems.